Compass Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Compass Therapeutics (CMPX).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

13Buy

1Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$9Upside to Avg. PT+876.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Craig-Hallum	Albert Lowe	PT Cut	Buy	$15→$8
Sep 23, 2026	Citizens	Reni J. Benjamin	PT Cut	Market Outperform	$10→$4
Sep 23, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$8→$4
Sep 23, 2026	Wedbush	Robert Driscoll	Downgrade	Outperform→Neutral	$5→$1
Sep 23, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$24→$12
Aug 7, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$4→$6
Apr 28, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$13→$7
Apr 28, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$10
Apr 27, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$24
Apr 27, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$30
Mar 24, 2026	Guggenheim	Michael Schmidt	Maintained	Buy	$12
Jan 6, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$30
Jan 5, 2026	William Blair	Matt Phipps	Initiate	Outperform	—
Dec 3, 2025	Cantor Fitzgerald	Li Watsek	Initiate	Overweight	—
Dec 3, 2025	Citizens	Reni Benjamin	Initiate	Market Outperform	$10
Dec 3, 2025	Canaccord Genuity	John Newman	Initiate	Buy	$10
Nov 5, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$30
Oct 6, 2025	LifeSci Capital	—	Initiate	Outperform	$10
Aug 12, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$32
Aug 12, 2025	Guggenheim	Michael Schmidt	PT Raise	Buy	$10→$12

More with Benzinga EdgeGet Access

Analyst Ratings News

This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.

Avi Kapoor

PRO
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.

Benzinga Newsdesk

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.

Avi Kapoor

PRO
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4

Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $8 to $4.

Benzinga Newsdesk

PRO
Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.

Benzinga Newsdesk

Compass Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Compass Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

PRO
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

PRO
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4

PRO
Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

PRO
Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

People Also Watch

People Also Watch

Compass Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Compass Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

PROCraig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

PROCitizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4

PROGuggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

PROWedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

People Also Watch

People Also Watch

PRO
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

PRO
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4

PRO
Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

PRO
Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1